Shiny Mathewkutty, MD
Cardiology · Dallas, TXNPI 1235339961
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 68.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $8,397 and has fallen 76.0% since, to $2,015 in 2025. Among cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $149.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$16K
- Medtronic$6K
- Abbott$259
- Pfizer$189
- AstraZeneca$110
- Terumo Medical Corporation$99
- plus $471 from 13 others
What the payments were for
- Consulting fees$12,40053%
- Travel & lodging$6,61728%
- Food & beverage$4,49919%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $16,144 |
| Medtronic(2 entities) | 84 | $6,257 |
| Abbott | 12 | $259 |
| Pfizer | 9 | $189 |
| AstraZeneca | 7 | $110 |
| Terumo Medical Corporation | 2 | $99 |
| Amgen | 6 | $97 |
| Edwards Lifesciences | 3 | $62 |
| Novartis | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Bayer | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Johnson & Johnson | 1 | $21 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL HEART$4,000
- GENERAL - THERAPIES$3,850
- COREVALVE EVOLUT R$2,440
- CoreValve Evolut$1,809
- AMS$207
How this compares
$23,530 in reported general payments places this provider in the 95th percentile of 33 cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 315 | $340,475 |
| XareltoRivaroxaban | 228 | $240,763 |
| EntrestoSacubitril/Valsartan | 145 | $134,439 |
| Repatha SureclickEvolocumab | 148 | $110,142 |
| Praluent PenAlirocumab | 56 | $36,331 |
| FarxigaDapagliflozin Propanediol | 34 | $30,796 |
| JardianceEmpagliflozin | 30 | $25,155 |
| BrilintaTicagrelor | 15 | $13,441 |
| Metoprolol Succinate | 847 | $8,121 |
| NexletolBempedoic Acid | 14 | $5,634 |
| Potassium Chloride | 169 | $4,435 |
| Ezetimibe | 135 | $3,888 |
| Atorvastatin Calcium | 510 | $3,232 |
| Rosuvastatin Calcium | 449 | $2,881 |
| Losartan Potassium | 386 | $2,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $189 | $340,475315 claims |
| Johnson & JohnsonXarelto | $21 | $240,763228 claims |
| NovartisEntresto | $59 | $134,439145 claims |
| AstraZenecaFarxiga, Brilinta | $110 | $44,23649 claims |
| Boehringer IngelheimJardiance | $34 | $25,15530 claims |
| Esperion Therapeutics, Inc.Nexletol | $17 | $5,63414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 cardiology providers in Texas.
Other cardiology in Dallas
- Adeniran AriyoDallas$1K
- William DanielDallas$0
- Henry HanDallas$0
- Susan MatuleviciusDallas$0
- Glynnis GarryDallas$0
- Fiona StrasserkingDallas$0
- Keri ShaferDallas$0
- Duwayne WillettDallas$0
- Laurel LeeDallas$0
- Satyam SarmaDallas$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.